BBIO in the 13F filings
Bridgebio Pharma Inc · CUSIP 10806X102
- Quarter end
- 30 Sep 2025
- the date the book describes
- Filed
- 17 Feb 2026
- latest of these filings; the earliest 12 Nov 2025
- Managers listing it
- 14
- at least, of 95 tracked, among listed positions
- Comparable managers
- 95
- filed both Q2 2025 and Q3 2025; 13 listed it in both
- Shares listed
- 45,143,575
- combined, among listed positions
- Reported value
- $2.3bn
- combined, at the quarter end
Among the 95 comparable managers: 5 buyers (opened or added shares) and 9 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing BBIO in Q3 2025
14 of 14 holders
Largest increases and reductions, by shares
Increases
- Farallon Capital Management LLCexisting position · 8,192,000 shares now+292,000
- D. E. Shaw & Co.existing position · 2,252,762 shares now+171,509
- Freestone Grove Partners LPnew position · 93,469 shares now+93,469
- Artisan Partners LPexisting position · 331,302 shares now+13,015
- Polen Capital Management LLCexisting position · 36,164 shares now+515
Reductions
- Viking Global Investors LPexisting position · 15,977,849 shares now-2,577,526
- Capital Research Global Investorsexisting position · 1,933,126 shares now-2,055,172
- Woodline Partners LPexisting position · 198,318 shares now-1,506,482
- Balyasny Asset Management LLCexisting position · 1,014,677 shares now-626,943
- Janus Henderson Group Ltdexisting position · 8,741,079 shares now-535,453
New positions and exits
New (1)
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2019 | 2 | $719m | n.a. | n.a. |
| Q3 2019 | 1 | $572m | n.a. | n.a. |
| Q4 2019 | 2 | $1.0bn | n.a. | n.a. |
| Q1 2020 | 3 | $824m | n.a. | n.a. |
| Q2 2020 | 4 | $926m | n.a. | n.a. |
| Q3 2020 | 4 | $1.1bn | n.a. | n.a. |
| Q4 2020 | 5 | $2.0bn | n.a. | n.a. |
| Q1 2021 | 5 | $1.9bn | n.a. | n.a. |
| Q2 2021 | 5 | $1.8bn | n.a. | n.a. |
| Q3 2021 | 4 | $1.4bn | n.a. | n.a. |
| Q4 2021 | 2 | $452m | n.a. | n.a. |
| Q1 2022 | 2 | $276m | n.a. | n.a. |
| Q2 2022 | 2 | $246m | n.a. | n.a. |
| Q3 2022 | 3 | $271m | n.a. | n.a. |
| Q4 2022 | 2 | $204m | n.a. | n.a. |
| Q1 2023 | 4 | $477m | n.a. | n.a. |
| Q2 2023 | 2 | $463m | n.a. | n.a. |
| Q3 2023 | 9 | $898m | n.a. | n.a. |
| Q4 2023 | 9 | $1.3bn | 1 | 7 |
| Q1 2024 | 7 | $1.1bn | 5 | 2 |
| Q2 2024 | 4 | $826m | 2 | 0 |
| Q3 2024 | 8 | $927m | 7 | 0 |
| Q4 2024 | 7 | $1.2bn | 4 | 3 |
| Q1 2025 | 9 | $1.6bn | 6 | 3 |
| Q2 2025 | 15 | $2.3bn | 11 | 4 |
| Q3 2025 | 14 | $2.3bn | 5 | 9 |
| Q4 2025 | 18 | $4.3bn | 22 | 12 |
| Q1 2026 | 20 | $4.4bn | 20 | 14 |
| Q2 2026 | 18 | $4.5bn | 24 | 15 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
BBIO and LLY →BBIO and JNJ →BBIO and VRTX →Choose a stock to compare with BBIO →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own BBIO, latest filings →Back to the 13F Explorer →